In 2010, Russia, the plant "Sanofi-Aventis East" in the Orel region began production of high-quality innovative insulin analogues — drugs for the treatment of diabetes. Capacity of the plant is sufficient to meet the needs of the Russian market in high-tech insulin.
November 15, 2011 at the Analytical Center under the Government of the Russian Federation held a quarterly seminar meeting with the heads of permanent missions administrations of the Russian Federation on the theme: "The participation of the state and business in the development and localization of innovative production of essential drugs in Russia."
During the seminar meeting discussed the issue of substantial growth in recent years, the level of socially significant diseases among the population of Russia, in particular, diabetes mellitus (DM). Particular attention was paid to the influence of the disease on the economic and demographic situation in the country and the need for further development of production in the Russian innovative drugs for the treatment of diabetes. It was also noted the importance of the start of federal programs aimed at early detection and subsequent comprehensive treatment of diabetes on internationally accepted standards, and the need to ensure access of patients to modern innovative drugs, and the role of government and business in the implementation of these directions.
As an example, the localization of high-tech production in the territory of the Russian Federation, a strategy of the pharmaceutical industry in Russia — the program "Pharma 2020", was awarded the international company "Sanofi". Today it is the only international company from among the representatives of the "big pharma", producing in Russia, at its plant "Sanofi-Aventis East" in Orel, innovative drugs for the treatment of diabetes.
Raised at the seminar topic is very relevant today. According to experts, diabetes is ranked third in the world in the prevalence after cardiovascular diseases and cancer. Analysis of the incidence rate of growth has allowed the experts of the World Health Organization (WHO) called diabetes "non-infectious epidemic" of our time. If in 1972 there were 70 million people with diabetes, and in 2010 — 285 million (4.75% of the world population).
As pointed out in his speech, Professor Alexander Ametov, Head of the Department of Endocrinology RMAPO Health Ministry of Russia, "the problem of diabetes relates to society as a whole. Should be established to inform the population in order to early detect possible cases and to avoid the development of severe consequences. World Diabetes Day, which is celebrated on November 14, is also intended to highlight the broader problem of non-infectious epidemic of the XXI century. "Fight Diabetes" — is fundamentally wrong wording. We need to control this disease, as long as we can not cure it. Control — which means to reduce the risk of complications, which ultimately means a benefit to society as a whole. Indeed, diabetes is the leading cause of blindness — diabetic retinopathy, vascular disorders of nervous system diseases, and in 40-45% of cases — the cause of non-traumatic lower limb amputations. There is not a body that would not suffer as a result of diabetes. "
In Russian diabetic suffers from 2 to 4% of the population. Officially, the Russian Federation registered 3.4 million patients with this disease. However, studies conducted by the International Diabetes Federation (IDF), suggest that in fact, taking into account the undiagnosed cases, they are 3-4 times more, or about 10 million people. Speakers at the seminar meeting stressed the urgency of the problem of providing such a large number of patients is vitally important to them drugs for the treatment of diabetes, and, in particular, insulin. International practices diabetes therapy is the timely appointment of insulin analogues for the prevention of serious complications.
Speaking about the treatment of complications of diabetes, Professor Rose Ismailovna Yagudin, Head of Department of the organization of drug supply and pharmacoeconomics 1st MGMU them. Sechenov, emphasized: "The economic burden of diabetes is very high. The cost of treatment of only some of the complications of diabetes of the second type of cost to the state in the following amounts per year: diabetic retinopathy — 15 billion rubles., Diabetic foot — 23.8 billion rubles., Lower limb amputation — 4.8 billion rubles. As with any other disease, it is necessary to take into account both the direct costs of treatment, for example, the cost of drug supply, and indirect costs, such as costs due to the patient’s disability. "
Unfortunately, insulin analogues, the most advanced products to date, other than greater security and better tolerated, have not been made until recently in the Russian Federation. However, the situation has changed for the better since 2010, these innovative insulins are produced at "Sanofi-Aventis East" in the Oryol region. Capacity of the plant is sufficient to meet the needs of the Russian market in high-tech insulin.
Galkova Tatiana, Director of Communications "Sanofi Russia", emphasized: "Sanofi has 90 years of experience in the development and manufacture of drugs to combat diabetes and that is why the company has opened in Russia the production of high-quality innovative insulin analogs to improve the quality of life for millions of Russian patients with diabetes. We are proud to be the first to launch this production as soon as possible by performing a transfer of technology ".
The speakers agreed on the need for preventive measures aimed at early detection of signs of diabetes in the population of all the subjects of the Russian Federation as well as the smooth provision of identified patients domestic innovative insulin preparations. In addition, the participants of the seminar-meeting noted the critical importance of and the need for educational programs for patients with diabetes, as well as for medical professionals to improve the level of knowledge on modern methods of treatment of this disease and minimize the risks to public health in all regions of the Russian Federation.